Gaetan LEBLAY
Ascot
Summary
Developing Talent, Driving Growth and Delivering Solutions
Overview
25
25
years of professional experience
Work History
VP EMEA Customer and Data Strategy
Janssen
UK
01.2023 - Current
- Vice President, Board member of Janssen EMEA Strategy Organization.
- Challenges: Implementation of a new operating model for EMEA, turn-around of the regional organization and lead change management, lead business operations and platforms for EMEA, lead strategic planning and business reviews for EMEA and Senior Leaders, development of a launch excellence model, deployment of GenAI initiatives.
- Achievements: successful reorganization in 4 months, strategic and competitive reports integrated to corporate governance, successful implementation of the new marketing operations (Phoenix, OneCampaign, Brand Excellence).
Managing Director for UK and Ireland
Janssen
UK
01.2019 - 01.2023
- Vice President, Board member of Janssen EMEA.
- Board member of ABPI and American Chamber of Commerce.
- Challenges: Strategy, financial and operational responsibilities large PnL ($1.2B), lead market access with NICE/NHS, business transformation and digitalization, multiple crisis managements, COVID-19 vaccine, VPAS strategy and negotiations.
- Achievements: +50% NTS growth and +88% new patients' growth since 2019, moved from 8th to 3rd industry rank, best Darzalex launch in G5 with 75% share, new strategic vision and capabilities (digital, advanced analytics), complete rotation of the leadership team and a turn-around of the organization, unlocked multiple access dossiers (oncology, immunology, neurology), developed new business model (JNJ x-sectors, public private), policy shaping with multiple engagement at upmost senior levels, awarded best Brexit-readiness in Life Science by the Health minister.
Managing Director for Central Europe
Janssen
Hungary
01.2016 - 01.2019
- Vice President, Board member of EMEA Mid-size Markets.
- Challenges: Strategy, financial and operational responsibilities for 12 markets, lead affiliates through the next phase of growth, lead diverse and multi-cultural teams, gain market access for transformational innovations, build new capabilities and talent pipeline, create a culture fostering patient centric model.
- Achievements: increased the size of the regional footprint and sales by ~50% in 3 years ($220M), commanded #1 or #2 positions for all promoted brands, demonstrated value to governments and payers, gained access for high value drugs in complex healthcare systems (i.e Darzalex, Tremfya, Zytiga), completed CE re-organization with county archetyping, developed the next generation of local leaders (5 country directors), collaborated with the local authorities on healthcare policy, ensured compliance to highest ethical and business standards.
Global Franchise Commercial Leader (Oncology, DAS)
Janssen
USA
01.2014 - 01.2016
- Senior Director, Board member of Global ONcology Leadership Team.
- Global commercial strategy, responsible for early development, late development and in market compounds of gynecology - urology portfolio.
- Challenges: Portfolio strategic positioning, pipeline creation with R&D, License and Acquisition, global Access and Reimbursement strategies, global public health and healthcare transformation (reforms, pricing, new business models).
- Achievements: strategy acceleration on Solid Tumors, expansion of the Prostate franchise, 3 partnerships completed, 8 NMEs declarations, 5 phases III trials (i.e Zytiga's Latitude, Apalutamide), 100+ reimbursements, 4 talent acquisitions and successful development, 5 publications/posters in market access.
Global Marketing Leader in Oncology (Prostate Cancer)
Janssen
USA
01.2013 - 01.2014
- Senior Director, GU Oncology.
- Global responsibilities of strategic marketing, coordination of access and medical strategies.
- Challenges: Integration of ARN-509 (Erleada), global strategy for commercial, access and reimbursement, Life Cycle Management.
- Achievements: phases III registration trials, significant data generation efforts for both medical affairs and market access perspectives (RWE), launch in Japan, recognition of high value at re-negotiation, healthcare policy shaping.
Business Unit Director (Oncology & Hematology)
Janssen
France
01.2011 - 01.2013
- Senior Director, Board member of French operating company.
- Challenges: responsible for value strategy, launch of breakthrough oncology drugs, turnover of Oncology and Hematology franchises, access and reimbursement.
- Achievements: best Zytiga launch in EMEA and best oncology launch in France; 65% growth across portfolio in 3 years, organization transformation and creation of an oncology talent pool, value management and drug effectiveness.
Cross-Regional Brand Leader, Global/EMEA
Janssen
France
01.2009 - 01.2010
- Director
- Challenges: led global marketing activities for Reminyl (Alzheimer), affordability in elderly patients, partnership with Shire global alliance.
- Achievements: successful collaboration with Shire, developed partnership with Karolinska Institute on health economics (Nobel Prize Academy).
Franchise Director (Anesthesiology)
Janssen
France
01.2007 - 01.2009
District Sales Manager (Neurology)
Janssen
France
01.2005 - 01.2007
Senior Analyst
Janssen
France
01.2003 - 01.2005
Project Director and consultant
Groupe SQLI
France
01.1999 - 01.2002
Education
Executive Education, R&D Leadership Program
Harvard Business School
USAMBA, with Honors (Dean's list) -
Warwick Business School
United Kingdom /2002 - 01.2003
Bachelor of Arts - Economics, with Honors
ESSEC and Stockholm University
France & Sweden /1993 - 01.1997
Skills
Leading diversity of businesses and people: Seasoned global executive experienced in:
- Managing complex P&L in G5 as well as Mid-Size markets and delivering growth
Growth:
- Managing diverse business lifecycles (start-up, turn-around, launch, L&A) in multiple therapeutic areas
Talent development:
- Advancing pipeline development of JNJ solid tumors franchise at global level
Strategy:
- Leading and developing teams at global, regional and local levels
- Discovering and championing talents and diversity internationally
Pipeline development:
- Demonstrating successful interactions with Payers and key stakeholders in multiple Healthcare Systems
Patient Access:
- Garnering market access of transformational innovations and gaining market share in both established and emerging markets
Established and Emerging Markets:
- Turning around organization to create new business cycles, improving productivity and improving customer impact
Languages
English: fluent
Master or proficient
C2
French: native
Master or proficient
C2
Spanish
Intermediate
B1
Swedish
Intermediate
B1
Hobbies
- Rugby
- Morgan horses
Publications
PLOS-Global Public Health, 2022:
- Differentials in clinical severity and other patient activity indicators amongst Black and South Asian cancer patients in England.
The Pharma Letter, 2022:
- Healthcare in a post-COVID world: What have we learnt?
PharmaPhorum, 2021:
- Preparing for a pandemic starts with creating a mentally resilient society.
Future Health and WPI, 2021:
- The Economics of Health: How the healthcare sector can support the UK economic recovery.
Digital Health, 2021:
- How data is shaping the future of healthcare
PharmaPhorum, 2020:
- Leading during the Covid-19 crisis (interview)
The Times - Raconteur, 2019:
- Big data can help rescue healthcare.
Cancer, 2017:
- Impact of Subsequent Metastases on Costs and Medical Resource Use in Prostate Cancer Patients Initially Diagnosed with Localized Disease.
AUA, 2016:
- The Impact of Subsequent Metastases on Survival and Medical Costs in Prostate Cancer Patients.
EAU, 2016:
- The Impact of Subsequent Metastases on Survival and Medical Costs in Prostate Cancer Patients.
ASCO-GU, 2016:
- The Impact of Subsequent Metastasis on Medical Costs in Medicare Patients with Prostate Cancer.
ASCO-GU, 2016:
- Medical Resource Use and Costs from Subsequent Metastases in Prostate Cancer Patients Initially Diagnosed with Loco-regional Disease.
2003:
- Value-Based Marketing in the Pharmaceutical Industry, dissertation, University of Warwick.
Timeline
VP EMEA Customer and Data Strategy
Janssen
01.2023 - Current
Managing Director for UK and Ireland
Janssen
01.2019 - 01.2023
Managing Director for Central Europe
Janssen
01.2016 - 01.2019
Global Franchise Commercial Leader (Oncology, DAS)
Janssen
01.2014 - 01.2016
Global Marketing Leader in Oncology (Prostate Cancer)
Janssen
01.2013 - 01.2014
Business Unit Director (Oncology & Hematology)
Janssen
01.2011 - 01.2013
Cross-Regional Brand Leader, Global/EMEA
Janssen
01.2009 - 01.2010
Franchise Director (Anesthesiology)
Janssen
01.2007 - 01.2009
District Sales Manager (Neurology)
Janssen
01.2005 - 01.2007
Senior Analyst
Janssen
01.2003 - 01.2005
Project Director and consultant
Groupe SQLI
01.1999 - 01.2002
Executive Education, R&D Leadership Program
Harvard Business School
MBA, with Honors (Dean's list) -
Warwick Business School
/2002 - 01.2003
Bachelor of Arts - Economics, with Honors
ESSEC and Stockholm University
/1993 - 01.1997
Similar Profiles
FAWZI MAYOUFFAWZI MAYOUF
Senior Product Specialist Neuroscience Line at JanssenSenior Product Specialist Neuroscience Line at Janssen
Judith ShusterJudith Shuster
Sr. Director CMCRA at JanssenSr. Director CMCRA at Janssen
Mary ArceMary Arce
Senior Site Manager at JanssenSenior Site Manager at Janssen